NASDAQ : ANTX
AN2 Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.53 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 170.95M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 160.95M |
| Enterprise Value | 82.56M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 37.74M |
| Shares Outstanding | 37.74M |
| Shares Change (YoY) | +16.31% |
| Shares Change (QoQ) | +31.42% |
| Owned by Insiders (%) | 4.91% |
| Owned by Institutions (%) | 47.22% |
| Float | 22.29M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.17 |
| P/TBV Ratio | 2.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 14.32 |
| Quick Ratio | 14.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -50.12% |
| Return on Assets (ROA) | -30.80% |
| Return on Invested Capital (ROIC) | -33.51% |
| Return on Capital Employed (ROCE) | -51.01% |
| Weighted Average Cost of Capital (WACC) | -0.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.73M |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.94 |
| 52-Week Price Change | +256.91% |
| 50-Day Moving Average | 4.87 |
| 200-Day Moving Average | 4.09 |
| Relative Strength Index (RSI) | 51.08 |
| Average Volume (20 Days) | 306,796 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.89M |
| Short Previous Month | 2.49M |
| Short % of Shares Out | 7.65% |
| Short % of Float | 12.96% |
| Short Ratio (days to cover) | 8.92 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -38.81M |
| Pretax Income | -36.28M |
| Net Income | -36.28M |
| EBITDA | n/a |
| EBIT | -38.81M |
| Earnings Per Share (EPS) | -$1.04 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 78.39M |
| Total Debt | n/a |
| Net Cash | 78.39M |
| Net Cash Per Share | $2.08 |
| Equity (Book Value) | 75.92M |
| Book Value Per Share | 2.09 |
| Working Capital | 74.41M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -30.68M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -30.68M |
| FCF Per Share | -$0.81 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -16.31% |
| Shareholder Yield | -16.31% |
| Earnings Yield | -24.39% |
| FCF Yield | -18.48% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $9.00 |
| Price Target Difference | 111.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |